These in vivo and in vitro studies reveal the role of HER2 amplification in EGFR-TKIs resistance and provide a theoretical basis for evaluating the possibility of targeting HER2 therapy in EGFR-mutant NSCLC patients with acquired resistance to EGFR-TKIs. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.